D3 Bio secures $108 million in Series B financing led by IDG Capital and SongQing Capital to advance global clinical programs for innovative oncology therapeutics.
Amount Raised
$108 Million
Round Type
Series B
Investors
Description
D3 Bio completed a $108 million Series B financing round backed by investors including IDG Capital and SongQing Capital. Proceeds will support a global Phase III pivotal program for D3 Bio’s lead asset, elisrasib. The funding will also aid the development of D3 Bio's pipeline of targeted and immuno-oncology programs. This demonstrates strong investor confidence in D3 Bio's vision and capabilities.
Quick answer
D3 Bio raised $108 Million in a Series B round, dated December 10, 2025. Investors: WuXi AppTec's Corporate Venture Fund, Hong Shan, MPCi, Songqing Capital, Temasek, Mp Ci, Medicxi and IDG Capital.
- How much did D3 Bio raise?
- D3 Bio raised $108 Million in a Series B round on December 10, 2025.
- Who invested in D3 Bio?
- WuXi AppTec's Corporate Venture Fund, Hong Shan, MPCi, Songqing Capital, Temasek, Mp Ci, Medicxi and IDG Capital are named as investors in this round.
- What does D3 Bio do?
- D3 Bio is a globally orientated, clinical stage biotechnology company that focuses on the discovery, development, and registration of new medicines in oncology and immunology.
- Who are the decision-makers at D3 Bio?
- Fundz holds 2 contacts at D3 Bio, including the Co-Founder & Cfo/cbo. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as D3 Bio that raised within 45 days of this round, from Fundz verified event records.
- Corxel Pharmaceuticals raised $287M (Series D) on January 22, 2026.
- ImmunoMet Therapeutics raised $842K on January 21, 2026.
- Os Therapies raised $3.5M on January 14, 2026.
- Vivere Oncotherapies raised $10M (Funding Round) on January 13, 2026.
- Tessera Defense & Homeland Security Inc. raised $3.3M on January 13, 2026.
- Aurora Therapeutics raised $16M (Seed) on January 9, 2026.
Who to call at D3 Bio, and when
A new round usually means D3 Bio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day D3 Bio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at D3 Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at D3 Bio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment D3 Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansD3 Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.